Granulocytapheresis in the treatment of severe alcoholic hepatitis: a case series
Related Experiment Video
Updated: Jun 19, 2026
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Judith M Morris1, Sheila Dickson, Margaret Neilson
1Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK.
Objectives:
The management of alcoholic hepatitis remains controversial. Anti-tumour necrosis factor treatments have been studied recently. We piloted the use of granulocytapheresis (GCAP) in the management of severe alcoholic hepatitis.
Methods:
GCAP was performed on six patients with severe alcoholic hepatitis. Their clinical and laboratory progress was reviewed retrospectively.
Results:
Six of the patients underwent at least one session of GCAP. Three of the patients had coexistent renal failure and five of the six patients were corticosteroid nonresponders. All patients tolerated the procedure. However, three of the patients died during their hospital admission within 4 days of GCAP treatment. These three patients suffered from torrential variceal haemorrhage, multiorgan failure and pneumonia, respectively. Two patients died 18 and 25 days after their GCAP treatment, both with multiorgan failure. The survivor was the sole corticosteroid responder of the group. There was a trend towards a fall in serum bilirubin level after GCAP, but this did not reach significance.
Conclusion:
GCAP is tolerated in severe alcoholic hepatitis; however, we have no evidence of survival advantage with this treatment.
